0001127602-22-025018.txt : 20221107 0001127602-22-025018.hdr.sgml : 20221107 20221107160649 ACCESSION NUMBER: 0001127602-22-025018 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221103 FILED AS OF DATE: 20221107 DATE AS OF CHANGE: 20221107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRAZIER KENNETH C CENTRAL INDEX KEY: 0001181175 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 221365431 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-11-03 0000310158 Merck & Co., Inc. MRK 0001181175 FRAZIER KENNETH C MERCK & CO., INC. 126 E. LINCOLN AVENUE RAHWAY NJ 07065 1 1 Executive Chair Common Stock 2022-11-03 4 M 0 235000 0 A 935653.063 D Common Stock 2022-11-03 4 S 0 214617 98.6785 D 721036.063 D Common Stock 2022-11-03 4 S 0 20383 99.0926 D 700653.063 D Common Stock 2022-11-04 4 M 0 235000 0 A 935653.063 D Common Stock 2022-11-04 4 S 0 200190 98.5326 D 735463.063 D Common Stock 2022-11-04 4 S 0 34810 99.0804 D 700653.063 D Common Stock - 401(k) Plan 4481.1286 I By 401(k) Stock Option (Right to Buy) 53.06 2022-11-03 4 M 0 235000 0 D 2017-05-10 2026-05-09 Common Stock 235000 470769 D Stock Option (Right to Buy) 53.06 2022-11-04 4 M 0 235000 0 D 2017-05-10 2026-05-09 Common Stock 235000 235769 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Holdings include shares acquired in dividend reinvestment transactions. Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan. The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. /s/ Kelly E. W. Grez as Attorney-in-Fact for Kenneth C. Frazier 2022-11-07